Xenetic Biosciences reported a decline in royalty revenue and a widening net loss for the third quarter of 2026, largely driven by transaction-related expenses. The company is currently transitioning toward a clinical-stage focus on neutrophil extracellular traps (NETs) through its pending all-stock acquisition of Santersus AG.
Key Highlights
- Royalty revenue decreased 29% to $0.7 million, down from $1.0 million in the prior-year period, due to lower positive adjustments from the Takeda sublicense.
- General and administrative expenses surged 138% to $1.9 million, primarily reflecting legal and financial advisory fees associated with the Santersus transaction.
- Net loss widened to $1.7 million, or $0.72 per share, compared to a $0.5 million loss in the third quarter of 2025.
- Cash and cash equivalents stood at $5.8 million as of September 30, 2026, providing a limited runway as the company pursues its M&A strategy.